Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KCNB1 | Q14721 | 3/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10262850 | 0.92 | KLKB1 (0.42) | MMP2KLKB1TSHRKCNB1KMT2A | |
| SCHEMBL16907359 | 0.92 | KLKB1 (0.42) | MMP2KLKB1TSHRKCNB1KMT2A | |
| SCHEMBL12515365 | 0.92 | ALDH1A1 (0.43) | MMP2KLKB1TSHRKCNB1KMT2A | |
| SCHEMBL15317941 | 0.92 | KLKB1 (0.42) | MMP2KLKB1TSHRRAB9AKCNB1 | |
| SCHEMBL12767238 | 0.92 | ALDH1A1 (0.43) | MMP2KLKB1TSHRKCNB1KMT2A | |
| SCHEMBL10260677 | 0.91 | KLKB1 (0.41) | MMP2KLKB1TSHRKCNB1KCNA5 | |
| Delparantag SCHEMBL10267622 | 0.91 | ERAP2 (0.47) | MMP2KLKB1TSHR | |
| SCHEMBL15138936 | 0.91 | ERAP2 (0.47) | MMP2KLKB1TSHR | |
| SCHEMBL10261735 | 0.91 | KLKB1 (0.41) | MMP2KLKB1TSHRKCNB1KMT2A | |
| SCHEMBL19445643 | 0.91 | ALDH1A1 (0.43) | MMP2KLKB1TSHRKCNB1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252964-A1 | Compounds And Methods For Treating Candidiasis And Aspergillus Infections | POLYMEDIX, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20110098498-A1 | Processes For Preparing A Polymeric Compound | POLYMEDIX, INC. (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098498-A1 | Processes For Preparing A Polymeric Compound | F12, ALG1, ABCB11 | MMP2 2411/4885KLKB1 2057/4885TSHR 4534/4885 |
| US-20130252964-A1 | Compounds And Methods For Treating Candidiasis And Aspergillus Infections | ERG28, DPM1, MANBA | MMP2 169/4885KLKB1 747/4885TSHR 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.